EPRX vs ESLA

Eupraxia Pharmaceuticals Inc. vs Estrella Immunopharma, Inc. — Valuation Comparison 2026

EPRX

Biotechnology
Eupraxia Pharmaceuticals Inc.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$7.38
Last close
Models
7/13
Active
VS

ESLA

Biotechnology
Estrella Immunopharma, Inc.
Quality
3.1
out of 10
Value Trap
12
SAFE
Price
$1.14
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType EPRX Fair ValueEPRX Upside ESLA Fair ValueESLA Upside
Bayesian DCF Intrinsic $1.95 -73.5% $0.32 -71.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $4.13 -42.5% $1.39 +21.5%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $1.51 +35.0%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EPRX vs ESLA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EPRX vs ESLA — Which Stock Is More Undervalued?

ESLA scores higher with a 3.1/10 quality rating vs EPRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Eupraxia Pharmaceuticals Inc. (EPRX) and Estrella Immunopharma, Inc. (ESLA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EPRX currently trades at $7.38 with a QOC of 1.9/10, while ESLA trades at $1.14 with a QOC of 3.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).